Here are the latest quarterly results of VENUS REMEDIES. For more details, see the VENUS REMEDIES financial fact sheet and VENUS REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Dec-17 |
3
Mar-18 |
3
Jun-18 |
3
Sep-18 |
3
Dec-18 |
3
Mar-19 |
3
Jun-19 |
3
Sep-19 |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 931 | 932 | 655 | 809 | 691 | 864 | 708 | 801 | |
Other income | Rs m | 1 | 3 | 2 | 12 | 5 | 38 | 4 | 7 | |
Turnover | Rs m | 933 | 935 | 657 | 821 | 695 | 902 | 712 | 808 | |
Expenses | Rs m | 754 | 838 | 554 | 644 | 643 | 835 | 607 | 655 | |
Gross profit | Rs m | 177 | 94 | 101 | 165 | 47 | -61 | 102 | 145 | |
Depreciation | Rs m | 89 | 62 | 82 | 83 | 83 | 83 | 83 | 83 | |
Interest | Rs m | 84 | 98 | 77 | 91 | 94 | 0 | 60 | 49 | |
Profit before tax | Rs m | 5 | -62 | -56 | 3 | -125 | -105 | -37 | 20 | |
Tax | Rs m | 0 | 32 | 0 | -5 | -6 | -1 | 0 | 2 | |
Profit after tax | Rs m | 5 | -94 | -56 | 8 | -119 | -104 | -37 | 19 | |
Gross profit margin | % | 19.0 | 10.1 | 15.5 | 20.4 | 6.9 | -7.0 | 14.4 | 18.2 | |
Effective tax rate | % | 0.0 | -50.9 | 0.0 | -161.6 | 4.4 | 1.0 | 0.0 | 8.1 | |
Net profit margin | % | 0.6 | -10.1 | -8.5 | 1.0 | -17.3 | -12.1 | -5.2 | 2.3 | |
Diluted EPS | Rs | 0.5 | -8.2 | -4.9 | 0.7 | -10.4 | -9.1 | -3.2 | 1.6 | |
Diluted EPS (TTM) | Rs | 6.0 | -6.1 | -11.7 | -11.9 | -22.8 | -23.7 | -22.1 | -21.1 | |
![]() |
Read: VENUS REMEDIES 4QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: LUPIN INDRAPRASTHA MEDICAL DISHMAN PHARMA PANACEA BIOTECH INDOCO REMEDIES
Compare VENUS REMEDIES With: LUPIN INDRAPRASTHA MEDICAL DISHMAN PHARMA PANACEA BIOTECH INDOCO REMEDIES
Compare VENUS REMEDIES With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More